Androgen-independent growth of LNCaP prostate cancer cells is mediated by gain-of-function mutant p53

Cancer Research

Volumn 63, Issue 9, 2003, Pages 2228-2233

  Nesslinger, Nancy J ^a   Shi, Xu Bao ^a   DeVere White, Ralph W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MUTANT PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53;

ALLELE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; HORMONE DEPENDENCE; HUMAN; HUMAN CELL; MALE; MUTATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; TRANSACTIVATION; WESTERN BLOTTING;

ALLELES; ANDROGENS; CELL DIVISION; GENES, P53; HUMANS; MALE; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, ANDROGEN; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0038713470     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Huggins, C., and Hodge, C. V. Studies on prostatic cancer: The effects of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293-297, 1941
2. Kyprianou, N., English, H., and Isaacs, J. T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res., 50: 3748-3753, 1990
3. Isaacs, J. T. The biology of hormone refractory prostate cancer. Urol. Clin. North Am., 26: 263-273, 1999
4. Oh, W. K., and Kantoff, P. W. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol., 160: 1220-1229, 1998
5. Vogelstein, B., Lane, D., and Levine, A. J. Surfing the p53 network. Nature (Lond.), 408: 307-310, 2000
6. Navone, N. M., Troncoso, P., Pisters, L. L., Goodrow, T. L., Palmer, J. L., Nichols, W. W., von Eschenbach, A. C., and Conti, C. J. p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst., 85: 1657-1669, 1993
7. Heidenberg, H. B., Sesterhenn, I. A., Gaddipati, J. P., Weghorst, C. M., Buzard, G. S., Moul, J. W., and Srivastava, S. Alteration of the tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J. Urol., 154: 414-421, 1995
8. Chi, S-G., deVere White, R. W., Meyers, F. J., Siders, D. B., Lee, F., and Gumerlock, P. H. p53 in prostate cancer: frequent expressed transition mutations. J. Natl. Cancer Inst., 86: 926-933, 1994
9. Meyers, F. J., Gumerlock, P. H., Chi, S-G., Borchers, H., Deitch, A. D., and deVere White, R. W. Very frequent p53 mutations in metastatic prostate carcinoma and in matched primary tumors. Cancer (Phila.), 83: 2534-2539, 1998
10. Shi, X-B., Nesslinger, N. J., Deitch, A. D., Gumerlock, P. H., and deVere White, R. W. Complex functions of mutant p53 alleles from human prostate cancer. Prostate, 51: 59-72, 2002
11. Koivisto, P. A., and Rantala, I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J. Pathol., 187: 237-241, 1999
12. Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., and Levine, A. J. Gain of function mutations in p53. Nat. Genet., 4: 42-46, 1993
13. Shaulsky, G., Goldfinger, N., and Rotter, V. Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Res., 51: 5232-5437, 1991
14. Roemer, K. Mutant p53: Gain-of-function oncoproteins and wild-type p53 inactivators. Biol. Chem., 380: 879-887, 1999
15. deVere White, R. W., Deitch, A. D., Gumerlock, P. H., and Shi, X-B. Use of a yeast assay to detect functional alterations in p53 in prostate cancer: review and future directions. Prostate, 41: 134-142, 1999
16. Kokontis, J., Takakura, K., Hay, N., and Liao, S. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res., 54: 1566-1573, 1994
17. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B., and Balk, S. P. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Res., 59: 2511-2515, 1999
18. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., vanRooij, H. C. J., Trapman, J., Brinkmann, A. O. and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 173: 534-540, 1990
19. Wen, Y., Hu, M. C-T., Makino, K., Spohn, B., Bartholomeusz, G., Yan, D-H., and Hung, M-C. HER-2/eu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res., 60: 6841-6845, 2000
20. Raffo, A. J., Perlman, H., Chen, M-W., Day, M. L., Streitman, J. S., and Buttyan, R. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res., 55: 4438-4445, 1995
21. Eastham, J. A., Stapelton, A. M. F., Gousse, A. E., Timme, T. L., Yang, G., Slawin, K. M., Wheeler, T. M., Scardino, P. T., and Thompson, T. C. Association of p53 mutations with metastatic prostate cancer. Clin. Cancer Res., 1: 1111-1118, 1995
22. Isaacs, W. B., Carter, B. S., and Ewing, C. M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 51: 4716-4720, 1991
23. Gingrich, J. R., Barrios, R. J., Kattan, M. W., Nahm, H. S., Finegold, M. J., and Greenberg, N. M. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res., 57: 4687-4691, 1997
24. Burchardt, M., Burchardt, T., Shabsigh, A., Ghafar, M., Chen, M-W., Anastasiadis, A., de la Taille, A., Kiss, A., and Buttyan, R. Reduction of wild type p53 function confers a hormone resistant phenotype on LNCaP prostate cancer cells. Prostate, 48: 225-230, 2001
25. van Oijen, M. G. C. T., and Slootweg, P. J. Gain-of-function mutations in the tumor suppressor gene p53. Clin. Cancer Res., 6: 2138-2145, 2000
26. Miyashita, T., Harigai, M., Hanada, M., and Reed, J. C. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res., 54: 3131-3135, 1994
27. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H-G., Lin, H-K., Liebermann, D. A., Hoffman, B., and Reed, J. C. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene, 9: 1799-1805, 1994
28. Eastham, J. A., Grafton, W., Martin, C. M., and Williams, B. J. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J. Urol., 164: 814-819, 2000
29. Shenk, J. L., Fisher, C. J., Chen, S-Y., Zhou, X-F., Tillman, K., and Shemshedini, L. p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J. Biol. Chem., 276: 38472-38479, 2001
30. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997
31. Manin, M., Baron, S., Goossens, K., Beaudoin, C., Jean, C., Veyssiere, G., Verhoeven, G., and Morel, L. Androgen receptor expression is regulated by the PI3-kinase/Akt pathway in normal and tumoral epithelial cells. Biochem. J., 366: 729-736, 2002
32. Murillo, H., Huang, H., Schmidt, L. J., Smith, D. I., and Tindall, D. J. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology, 142: 4795-4805, 2001
33. Lin, H-K., Yeh, S., Kang, H-Y., and Chang, C. Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. USA, 98: 7200-7205, 2001
34. Chan, T. O., Rittenhouse, S. E., and Tsichlis, P. N. AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. Annu. Rev. Biochem., 68: 965-1014, 1999
35. Shi, X-B., Gumerlock, P. H., and DeVere White, R. W. Molecular biology of prostate cancer. World J. Urol., 14: 318-328, 1996
36. Yang, X., Pater, A., and Tang, S. C. Cloning and characterization of the human BAG-1 gene promoter: upregulation by tumor-derived p53 mutants. Oncogene, 18: 4546-4553, 1999
37. Froesch, B. A., Takayama, S., and Reed, J. C. BAG-IL protein enhances androgen receptor function. J. Biol. Chem., 273: 11660-11666, 1998